Roche Investor Day 2010

Introduction (21:08) Severin Schwan F. Hoffmann-La Roche Ltd.
Translating science into innovative therapies (26:10) Richard Scheller F. Hoffmann-La Roche Ltd.
Harnessing therapeutic modalities (20:46) Jean-Jacques Garaud F. Hoffmann-La Roche Ltd.
Roche Partnering, enriching our portfolio (9:00) Dan Zabrowski F. Hoffmann-La Roche Ltd.
Diagnostics and personalised healthcare (22:36) Dan O Day F. Hoffmann-La Roche Ltd.
Q and A - Diversity of approaches to innovation (36:27) Speakers - "Diversity of approaches to innovation" F. Hoffmann-La Roche Ltd.
Sustainable growth through innovation (25:02) Pascal Soriot F. Hoffmann-La Roche Ltd.
Biosimilar - market dynamics and the Roche portfolio (14:29) Mike Doherty F. Hoffmann-La Roche Ltd.
Near-term opportunities (23:14) David Loew F. Hoffmann-La Roche Ltd.
Q and A - Sustainable growth (22:33) Speakers - "Sustainable growth" F. Hoffmann-La Roche Ltd.
New late-stage opportunities (49:26) Hal Barron F. Hoffmann-La Roche Ltd.
Roche unedited - Q and A with all speakers (27:39) all speakers F. Hoffmann-La Roche Ltd.

Webcast

Agenda:
“Diversity of approaches to innovation”

Introduction: Severin Schwan, CEO Roche Group
Translating science into innovative therapies: Richard Scheller, Global Head gRED
Harnessing therapeutic modalities: Jean-Jacques Garaud, Global Head pRED
Roche Partnering, enriching our portfolio: Dan Zabrowski, Global Head Pharma Partnering
Diagnostics and personalised healthcare: Daniel O’Day, COO Diagnostics Division
Q&A

Sustainable growth through innovation: Pascal Soriot, COO Pharma Medicines
Biosimilar: market dynamics and the Roche portfolio: Mike Doherty, Global Head Regulatory, Pharma
Near-term opportunities: David Löw, Head Global Product Strategy, Pharma
Q&A

New late-stage opportunities: Hal Barron, Head Product Development & CMO, Pharma
“Roche unedited” - Q&A with all speakers